Ace Therapeutics is an expert in the field of liver disease research. We have extensive hands-on experience in targeting lipid metabolism to develop drugs for liver disease.
The liver plays an important role in the digestion, absorption, catabolism, synthesis, and transport of lipids. Therefore, liver function and lipid metabolism interact and influence each other. The most intuitive consequence of abnormal lipid metabolism is the resultant hepatic steatosis. Hepatic steatosis can lead to a number of serious diseases such as steatohepatitis, fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Therefore, timely regulation of lipid metabolism is a potential target for the treatment of liver disease as it progresses. We provide a comprehensive service to develop drugs that target lipid metabolism for the treatment of liver disease.
What Can We Do?
We have established well-established drug development services for different processes and different targets of lipid metabolism for liver disease to meet the needs of different investigators.
- Drug Development for Liver Disease Targeting PPAR
Given the important regulatory role of the peroxisome proliferator-activated receptor (PPAR) in lipid metabolism, we offer a comprehensive research service targeting the PPAR in the development of drugs for liver disease.
- Based on our small molecule compounds library, we will perform high-throughput screening of PPAR agonists based on different subtypes of PPAR.
- We will provide different liver disease models and PPAR gene deletion animal models for validating the effect of drug candidates.
- We will detect biomarkers of fatty acid metabolic processes by PCR, biochemical kits, and other methods to assess the effect of PPAR agonists on fat metabolism in liver disease.
- We will perform absolute quantification of specific lipids by quantitative lipidomics to investigate in depth the effects of candidate PPAR agonists on lipids and their modulation of the pathological process of liver disease.
- Drug Development for Liver Disease Targeting FXR
Given the important role of the farnesylate X receptors (FXR) in maintaining bile acid and cholesterol homeostasis and regulating fatty acid oxidation and hepatic glycogen synthesis, we offer high-quality services to target the FXR for the development of liver disease drugs.
- Given the involvement of FXR in enterohepatic regulation, we will perform a high-throughput screen targeting the enterohepatic regulation of FXR to screen for effective modulators. Meanwhile, we will evaluate the candidate drug activity by detecting lipid accumulation and real-time monitoring of gene expression of glucose homeostasis enzymes in experimental models.
- Given the modulatory effects of FXR on lipids, we combine target-based high-throughput screening with structure-based drug screening to screen for FXR agonists for the treatment of chronic liver disease.
- We have a well-established lipid quantification platform to enable precise lipid detection services.
Ace Therapeutics has an experienced team in the field of liver disease development. Our scientists will develop a professional service plan for you based on your research needs. If you would like to learn more about our services, please feel free to contact us.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
